Retinoblastoma protein switches the E2F site from positive to negative element - PubMed (original) (raw)
. 1992 Jul 16;358(6383):259-61.
doi: 10.1038/358259a0.
Affiliations
- PMID: 1321348
- DOI: 10.1038/358259a0
Retinoblastoma protein switches the E2F site from positive to negative element
S J Weintraub et al. Nature. 1992.
Abstract
Originally E2F sites were identified as elements in the promoters of adenovirus early genes that are necessary for activation of these genes by the early protein E1a (ref. 1). E2F promoter elements have been shown to be important for transcriptional activation of several genes critical for progression through the cell cycle. During the G1 phase of the cell cycle, the E2F protein forms a complex with the cell-cycle protein Rb (ref. 5) and it has been suggested that this binding of Rb to E2F inactivates E2F (ref. 5). Here we show that Rb-E2F is an active complex that, when bound to the E2F site, inhibits the activity of other promoter elements and thus silences transcription. We propose that the ability of this complex to inhibit transcription is integral to the function of Rb and provide evidence that E2F is a positive element in the absence of an active form of Rb. It has been shown that binding of Rb to E2F depends on the phosphorylation state of Rb (only the underphosphorylated form binds) and that the phosphorylation state of Rb changes during progression through the cell cycle. We therefore suggest that the E2F site alternates between a positive and negative element with the phosphorylation/dephosphorylation cycle of Rb. This cyclic activity may be responsible for activating and then inhibiting genes during the cell cycle.
Similar articles
- Mechanism of active transcriptional repression by the retinoblastoma protein.
Weintraub SJ, Chow KN, Luo RX, Zhang SH, He S, Dean DC. Weintraub SJ, et al. Nature. 1995 Jun 29;375(6534):812-5. doi: 10.1038/375812a0. Nature. 1995. PMID: 7596417 - Complexes containing the retinoblastoma gene product recognize different DNA motifs related to the E2F binding site.
Ouellette MM, Chen J, Wright WE, Shay JW. Ouellette MM, et al. Oncogene. 1992 Jun;7(6):1075-81. Oncogene. 1992. PMID: 1534398 - [Molecular cancer epidemiology--the present status and future possibilities].
Sakai T. Sakai T. Nihon Eiseigaku Zasshi. 1996 Feb;50(6):1036-46. doi: 10.1265/jjh.50.1036. Nihon Eiseigaku Zasshi. 1996. PMID: 8720930 Review. Japanese. - [Genetic and biochemical interactions of Rb and ras].
Takahashi C, Takegami Y, Shamma A. Takahashi C, et al. Seikagaku. 2009 Oct;81(10):873-83. Seikagaku. 2009. PMID: 19928527 Review. Japanese. No abstract available.
Cited by
- An intermediate Rb-E2F activity state safeguards proliferation commitment.
Konagaya Y, Rosenthal D, Ratnayeke N, Fan Y, Meyer T. Konagaya Y, et al. Nature. 2024 Jul;631(8020):424-431. doi: 10.1038/s41586-024-07554-2. Epub 2024 Jun 26. Nature. 2024. PMID: 38926571 Free PMC article. - MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation.
Ma J, Li L, Ma B, Liu T, Wang Z, Ye Q, Peng Y, Wang B, Chen Y, Xu S, Wang K, Dang F, Wang X, Zeng Z, Jian Y, Ren Z, Fan Y, Li X, Liu J, Gao Y, Wei W, Li L. Ma J, et al. Nat Commun. 2024 Feb 29;15(1):1871. doi: 10.1038/s41467-024-45796-w. Nat Commun. 2024. PMID: 38424044 Free PMC article. - Selective Occupation by E2F and RB of Loci Expressed by RNA Polymerase III.
Sizer RE, Butterfield SP, Hancocks LA, Gato De Sousa L, White RJ. Sizer RE, et al. Cancers (Basel). 2024 Jan 23;16(3):481. doi: 10.3390/cancers16030481. Cancers (Basel). 2024. PMID: 38339234 Free PMC article. - JHD205, A Novel Abemaciclib Derivative, Exerts Antitumor Effects on Breast Cancer by CDK4/6.
Ji J, Qin J, Wang X, Lv M, Hou X, Jing A, Zhou J, Zuo L, Liu W, Feng J, Qian Q, Liu Y, Wang X, Liu B. Ji J, et al. Anticancer Agents Med Chem. 2024;24(6):400-411. doi: 10.2174/0118715206265751231204190204. Anticancer Agents Med Chem. 2024. PMID: 38192142 - The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment.
Morrison L, Loibl S, Turner NC. Morrison L, et al. Nat Rev Clin Oncol. 2024 Feb;21(2):89-105. doi: 10.1038/s41571-023-00840-4. Epub 2023 Dec 11. Nat Rev Clin Oncol. 2024. PMID: 38082107 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources